<DOC>
	<DOCNO>NCT00736073</DOCNO>
	<brief_summary>The purpose study determine give Aprepitant 4 hour two day ERCP decrease risk develop pancreatitis ERCP .</brief_summary>
	<brief_title>A Trial Aprepitant For Prevention Post-Endoscopic Retrograde Cholangiopancreatography ( ERCP ) Pancreatitis</brief_title>
	<detailed_description>This study involve take drug Aprepitant mouth 4 hour ERCP day two day ERCP , attempt reduce risk pancreatitis cause ERCP . Pancreatitis , injury inflammation pancreas , common complication ERCP occur approximately 6 every 100 patient undergoing ERCP . It may result pain lead hospitalization , case , need procedure surgery . Aprepitant medication currently use prevent nausea vomit patient cause chemotherapy treatment cancer . It also approve prevention post-operative nausea vomit . There theoretical evidence animal study way Aprepitant work body may prevent pancreatitis .</detailed_description>
	<mesh_term>Pancreatitis</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<criteria>Patients select study undergo ERCP high risk development postERCP pancreatitis patient expect undergo sphincterotomy patient suspect sphincter oddi dysfunction patient know history past postERCP pancreatitis patient less 60 year age active pancreatitis pregnant know adverse reaction aprepitant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>pancreatitis</keyword>
</DOC>